# Cc Ethics Registration > Use when assembling ethics approvals and availability statements for a Cancer Cell (Cell Press) manuscript — IACUC animal approval, human-sample IRB/consent, biosafety, and data/code deposition statements. It governs compliance declarations; it does not design experiments or write methods detail. - Skill: `thedixitjain/cc-ethics-registration` (Agent Skill) - Install (CLI): `npx skillmds add thedixitjain/cc-ethics-registration` - Raw SKILL.md: https://api.skillmd.com/api/skills/thedixitjain/cc-ethics-registration/raw - Safety review: pending - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Security - Author: thedixitjain (https://skillmd.com/u/thedixitjain) - Updated: 2026-09-08 - Page: https://skillmd.com/skills/thedixitjain/cc-ethics-registration --- # Ethics, Approvals & Data Availability (cc-ethics-registration) ## When to trigger - The study uses animals, human samples, or hazardous agents - You need the IACUC / IRB / consent / biosafety statements - You need the **Data and code availability** statement and accessions - A clinical-translational component may need trial registration ## Animal work — IACUC - State that all animal procedures were **approved by the institutional IACUC** (or equivalent), with the **protocol number** and institution. - Confirm compliance with relevant national/institutional guidelines. - Pair with ARRIVE-style methods reporting (sample size, randomization, blinding, humane endpoints) handled in `cc-reporting-standards`. ## Human samples — IRB & consent - State **IRB / ethics committee approval** (institution + protocol). - State that **informed consent** was obtained (or a documented waiver and its basis). - Affirm compliance with the **Declaration of Helsinki** for human-subjects research. - For patient-identifiable genomic data, note controlled-access deposition (dbGaP/EGA) and any data-use limitations. - If a clinical trial provided samples/outcomes, give the **registration number** (e.g., ClinicalTrials.gov) and registry. ## Biosafety & other compliance - Note biosafety level / institutional biosafety approval for pathogens, lentivirus/retrovirus, or hazardous reagents where relevant. - Recombinant DNA / dual-use considerations if applicable. - Disclose any field-collected or regulated materials (permits). ## Data and code availability (Cell Press standard) Provide an explicit statement with three components: 1. **Data** — all newly generated datasets deposited and accessions listed (GEO/SRA for sequencing; dbGaP/EGA for controlled human genomics; PRIDE for proteomics; PDB/EMDB for structures; MetaboLights/Workbench for metabolomics). State public availability as of publication date. 2. **Code** — any original/custom code deposited in a citable repository with a DOI (e.g., Zenodo release of a GitHub tag). 3. **Other** — any additional information/reagents available from the lead contact on request. Accessions must also appear in the **Key Resources Table**. "Available on request" is not acceptable for the data types above. ## Authorship & disclosure (usually adjacent) - Author contributions (CRediT-style), competing-interests declaration, and funding statement are typically required — confirm current sections on the author page. ## Checklist - [ ] IACUC approval stated with protocol # and institution (if animals) - [ ] IRB/ethics approval + informed consent (or waiver) stated (if human samples) - [ ] Declaration of Helsinki compliance affirmed (human subjects) - [ ] Controlled-access deposition noted for patient-identifiable genomics - [ ] Trial registration number given (if a registered trial supplied data) - [ ] Biosafety / hazardous-agent approvals noted where relevant - [ ] Data availability: all accessions listed and in the KRT - [ ] Code deposited with a citable DOI - [ ] Competing interests, funding, and author contributions drafted ## Anti-patterns - "Animal experiments followed guidelines" with no IACUC approval/number - Human samples used with no IRB/consent statement - Genomic patient data with no controlled-access plan - "Data available upon request" for sequencing/proteomics/structures - Missing or vague competing-interests / funding declarations - Trial-derived data with no registration number ## Ethics pass for Cancer Cell Use this as a second-pass capability check. First lock the cancer context, mechanism, model system, validation chain, and translational boundary; then test whether the manuscript addresses cancer-biology reviewers who expect mechanistic oncology, translational relevance, and strong multi-modal validation. - **Primary move:** Check consent/approval, registration, safety, privacy, data sharing, and disclosure statements before claiming compliance. - **Decision ledger:** return `claim / evidence / blocker / next edit` rows so the next pass can patch the manuscript directly. - **Neighbor test:** compare against Cell for broader biology, Nature Cancer for oncology breadth, Clinical Cancer Research for clinical translation; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing. - **Verification floor:** before submission-ready advice, re-open `resources/official-source-map.md` for volatile rules and name the one unresolved fact that could change the recommendation. ## Output format ``` 【Animal】IACUC approval + protocol #? Y/N 【Human】IRB + consent + Helsinki? controlled-access if needed? Y/N 【Biosafety】approvals noted where relevant? Y/N 【Trial registration】number given (if applicable)? Y/N 【Data availability】accessions listed + in KRT? Y/N 【Code】DOI deposited? Y/N 【Disclosures】competing interests / funding / contributions? Y/N 【Next step】cc-writing-style or cc-submission ``` --- **Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `Cancer-Cell-Skills/skills/cc-ethics-registration/SKILL.md`